证券代码：002044 证券简称：美年健康 公告编号：2025-032 美年大健康产业控股股份有限公司 关于 2022 年员工持股计划第二个锁定期届满的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 美年大健康产业控股股份有限公司（以下简称"公司"）于 2022 年 9 月 13 日 召开第八届董事会第十五次（临时）会议、第八届监事会第五次（临时）会议及 2022 年 9 月 29 日召开 2022 年第五次临时股东大会，审议通过《公司 2022 年员 工持股计划（草案）及其摘要》、《关于<公司 2022 年员工持股计划管理办法> 的议案》等相关议案。具体内容详见公司于 2022 年 9 月 14 日及 2022 年 9 月 30 日披露在《中国证券报》、《上海证券报》、《证券时报》、《证券日报》和巨 潮资讯网（www.cninfo.com.cn）上的相关公告。 公司于 2023 年 6 月 30 日召开第八届董事会第二十六次（临时）会议、第八 届监事会第十四次（临时）会议及 2023 年 7 月 17 日召开 2023 年第四次临时股 东大会，审 ...

证券代码：002044 证券简称：美年健康 公告编号：2025-033 美年大健康产业控股股份有限公司 关于公司及下属子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 美年大健康产业控股股份有限公司（以下简称"公司"或"美年健康"）于 2024 年 12 月 13 日召开的第九届董事会第五次（临时）会议及 2024 年 12 月 30 日召开 的 2024 年第六次临时股东大会，审议通过了《关于公司及下属子公司申请融资额 度并提供担保的议案》，同意公司及部分下属子公司 2025 年度为公司及合并报表 范围内的子公司提供担保额度累计不超过人民币 49 亿元；同意公司向上海市中小 微企业政策性融资担保基金管理中心（以下简称"融资担保中心"）提供的连带责任 保证提供反担保。具体内容详见公司于 2024 年 12 月 14 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于公司及下属子公司申请融资额度并提供担保 的公告》（公告编号：2024-111）。 二、进展情况 近日，公司与浙江建设融资租赁有限公司（以下简 ...

Industry Rating - The industry investment rating is maintained at "Outperform the Market" [1] Core Insights - The medical services sector is under pressure in 2024 due to high base effects, but macroeconomic improvements are expected to drive a sustained recovery [2][5] - In Q1 2025, the demand for medical services has stabilized, leading to continuous profit improvement [3][5] - The gross profit margin has slightly declined, with 2024's margin at 37.02%, down 1.24 percentage points, and Q1 2025's margin at 36.14% [4][9] Summary by Sections 2024 Performance - The overall revenue for the medical services sector in 2024 is projected at 73.908 billion yuan, a year-on-year increase of 1.29% - The net profit attributable to shareholders is expected to be 4.857 billion yuan, a decrease of 16.37% - The net profit excluding non-recurring items is forecasted at 4.229 billion yuan, down 22.95% [2][9] Q1 2025 Performance - The total revenue for the medical services sector in Q1 2025 is 18.005 billion yuan, reflecting a year-on-year growth of 2.48% - The net profit attributable to shareholders is 1.325 billion yuan, showing a year-on-year increase of 16.24% - The net profit excluding non-recurring items is 1.266 billion yuan, up 18.21% [3][9] Profitability Metrics - The gross profit margin for 2024 is 37.02%, with a slight decline to 36.14% in Q1 2025 - The operating cash flow for Q1 2025 is 2.332 billion yuan, with a cash flow to net profit ratio of 158.22% [4][7]

Group 1 - Chongqing Pharmaceutical Holdings received a warning letter from the Chongqing Securities Regulatory Bureau due to issues with revenue recognition in 2023, leading to inaccurate financial disclosures [1] - The company has implemented multiple corrective measures and aims to enhance its financial accounting and internal control governance [1] - This incident reflects deficiencies in the company's financial management and disclosure practices, which may impact market confidence in the short term [1] Group 2 - Lu Kang Pharmaceutical responded to the Shanghai Stock Exchange's inquiry regarding its 2024 annual report, addressing concerns about land reserve income recognition and accounts receivable [2] - The company emphasized that its main distributors are closely related to its core business and that there are no abnormal sales activities [2] - This response demonstrates the company's commitment to regulatory compliance and transparency, which may bolster investor confidence [2] Group 3 - BeiGene plans to change its registered location from the Cayman Islands to Switzerland and will issue 133 million new shares to its wholly-owned subsidiary [3] - This move reflects the company's internationalization strategy and ongoing commitment to its equity incentive plan [3] - The actions taken are expected to enhance the company's long-term value and competitiveness in the global market [3] Group 4 - Merck China announced the cancellation of temporary surcharges on orders to China in response to the US-China agreement to suspend tariff increases for 90 days [4] - This decision is aimed at stabilizing customer relationships in the Chinese market and reducing operational costs [4] - The move highlights the sensitivity of global pharmaceutical companies to trade policy changes and their strategic adjustments in response [4] Group 5 - Meinian Health reported progress in acquiring partial equity in thirteen companies, including Yunnan Ciming Health Service Co., Ltd. [6] - The completion of business registration changes for two subsidiaries marks a significant step in the acquisition process [6] - This acquisition is part of the company's strategic plan to expand market share and strengthen its competitive position in the health examination industry [6]

Group 1 - The company held its 2024 annual general meeting on May 14, 2025, with a total of 1,263 participants representing 1,445,211,083 shares, accounting for 36.92% of the total shares [5][6][30] - The meeting was conducted in compliance with relevant laws and regulations, ensuring the legitimacy of the voting process and the qualifications of attendees [4][30] - All proposals presented at the meeting were approved without any rejections or modifications [2][30] Group 2 - The company approved several key reports, including the 2024 Board of Directors' work report, with 99.80% of votes in favor [7][9][10] - The 2024 financial budget report was also approved, receiving 98.47% approval from shareholders [12] - The proposal for the 2024 profit distribution plan was passed with 99.81% approval [13] Group 3 - The company announced the acquisition of partial equity in Yunnan Cimain Health Service Co., Ltd. and twelve other companies, which was approved in previous board and shareholder meetings [33][34] - The completion of business registration changes for Hohhot Meinian and Kunshan Cimain Health Check Center was reported [34][36] - The company’s subsidiaries acquired 48.87% and 41.58% stakes in Hohhot Meinian and Kunshan Cimain, respectively [36]

Core Viewpoint - The China Securities Index for Healthcare Equipment and Services has shown a slight decline of 0.23% recently, reflecting a mixed performance over different time frames, with a year-to-date decrease of 0.88% [1]. Group 1: Index Performance - The China Securities Index for Healthcare Equipment and Services closed at 13,568.19 points with a trading volume of 15.409 billion yuan [1]. - Over the past month, the index has increased by 2.13%, while it has decreased by 5.63% over the last three months [1]. - The index has a year-to-date decline of 0.88% [1]. Group 2: Index Composition - The index is composed of listed companies in the healthcare sector, selected from the broader China Securities Index to reflect the overall performance of healthcare-related securities [1]. - The top ten weighted companies in the index include Mindray Medical (9.73%), Aier Eye Hospital (8.29%), and United Imaging Healthcare (7.73%) [1]. - The index is primarily composed of companies listed on the Shenzhen Stock Exchange (61.00%) and the Shanghai Stock Exchange (39.00%) [1]. Group 3: Fund Tracking - Several public funds track the China Securities Index for Healthcare Equipment and Services, including Southern Asset Management's various funds and Tianhong's ETF [2].

证券代码：002044 证券简称：美年健康 公告编号：2025-031 美年大健康产业控股股份有限公司 关于收购云南慈铭健康服务有限公司等十三家公司 部分股权暨关联交易的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 美年大健康产业控股股份有限公司（以下简称"公司"）于 2023 年 10 月 25 日 召开第八届董事会第二十八次（临时）会议及 2023 年 11 月 10 日召开 2023 年第 六次临时股东大会，审议通过《关于收购云南慈铭健康服务有限公司等十三家公 司部分股权暨关联交易的议案》，同意公司下属子公司收购云南慈铭健康服务有 限公司等十三家公司股权，具体情况详见公司于 2023 年 10 月 26 日在巨潮资讯网 （www.cninfo.com.cn）发布的《关于收购云南慈铭健康服务有限公司等十三家公 司部分股权暨关联交易的公告》（公告编号：2023-098）。 近日，侯马美年大健康管理有限公司（以下简称"侯马美年"）、昆山慈铭健康 体检中心有限公司（以下简称"昆山慈铭"）完成了工商变更登记手续。具体情况如 下： 1、侯马美年大健康管理 ...

北京市天元律师事务所 关于美年大健康产业控股股份有限公司 2024 年度股东大会的 法律意见 京天股字（2025）第 255 号 致：美年大健康产业控股股份有限公司 美年大健康产业控股股份有限公司（以下简称"公司"）2024 年度股东大会（以 下简称"本次股东大会"）采用现场投票与网络投票相结合的方式召开，现场会议于 2025 年 5 月 14 日 14:30 在上海市静安区灵石路 697 号健康智谷 9 号楼三楼公司会 议室召开。北京市天元律师事务所（以下简称"本所"）接受公司聘任，指派本所律 师参加本次股东大会现场会议，并根据《中华人民共和国公司法》、《中华人民共 和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股 东会规则》"）以及《美年大健康产业控股股份有限公司章程》（以下简称"《公司 章程》"）等有关规定，就本次股东大会的召集、召开程序、出席会议人员的资格、 召集人资格、会议表决程序和表决结果等有关事宜出具本法律意见。 为出具本法律意见，本所律师审查了《美年大健康产业控股股份有限公司第九 届董事会第八次会议决议公告》《美年大健康产业控股股份有限公司第八届监事会 第二十九次 ...

证券代码：002044 证券简称：美年健康 公告编号：2025-030 美年大健康产业控股股份有限公司 2024 年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无否决或修改提案的情况，无涉及变更前次股东大会决议的 情况。 2、本次股东大会审议的全部议案已对中小投资者（指除上市公司的董事、监 事、高级管理人员以及单独或者合计持有上市公司5%以上股份的股东以外的股东） 的表决单独计票。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开的时间 （1）现场会议召开时间：2025 年 5 月 14 日（星期三）下午 14:30 （2）网络投票时间为：2025 年 5 月 14 日（星期三）9:15-15:00 1）通过深圳证券交易所交易系统进行网络投票的具体时间为 2025 年 5 月 14 日 9:15-9:25，9:30-11:30 和 13:00-15:00； 2）通过互联网投票系统进行网络投票的具体时间为 2025 年 5 月 14 日 9:15- 15:00 的任意时间。 2、现场会议召开地点：上海市 ...

美年健康（002044）公告，公司下属子公司收购云南慈铭健康服务有限公司等十三家公司部分股权，近 日，侯马美年大健康管理有限公司和昆山慈铭健康体检中心有限公司已完成工商变更登记。侯马美年注 册资本1500万元，股权结构为太原美年大健康科技健康管理有限公司出资863万元，占比57.5333%；侯 马经济技术开发区仁和房地产开发有限公司出资507万元，占比33.8000%；李登科出资130万元，占比 8.6667%。昆山慈铭注册资本1575.57万元，股权结构为昆山美大门诊部有限公司出资954.41万元，占比 60.5755%；南通美富健康产业投资合伙企业(有限合伙)出资471.16万元，占比29.9041%；南通美兆美年 健康产业并购投资基金(有限合伙)出资150万元，占比9.5204%。 ...